|Bid||10.81 x 800|
|Ask||10.90 x 2900|
|Day's Range||10.82 - 11.19|
|52 Week Range||10.82 - 25.96|
|Beta (3Y Monthly)||2.03|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.67|
Oklahoma is the first to go to trial with a case relying on nuisance laws normally invoked for minor property disputes involving things such as loud noises or bright lights. “It’s the first time this theory has actually gotten to trial in pharmaceutical litigation, so everybody will be watching to see if it works,” said Richard C. Ausness, a University of Kentucky law professor who monitors opioid litigation. Oklahoma Attorney General Mike Hunter claims J&J and Teva are liable for at least $10 billion in damages from the state’s two-decade surge in opioid addiction.
Gail Box vividly remembers the day in May 2011 when she first learned her 22-year-old son Austin, a University of Oklahoma linebacker, was abusing opioid painkillers: It was the day he died of an overdose. In a few months he had gone from taking pills prescribed for a back injury to illicitly obtaining more of the addictive drugs from acquaintances. Oklahoma Attorney General Mike Hunter's $17 billion lawsuit is the first to go to trial of more than 2,000 actions by state and local governments accusing opioid manufacturers of contributing to an epidemic linked to a record 47,600 overdose deaths in 2017, according to the U.S. Centers for Disease Control and Prevention.
The investors are taking advantage of sliding prices for notes issued by companies such as Endo International Plc, Mallinckrodt Plc and Teva Pharmaceutical Industries Ltd., which face allegations that they’ve fueled the opioid epidemic, and that they’ve engaged in price-fixing of generic drugs. Mallinckrodt is also in a legal battle with the U.S. over a plan to slash reimbursements on Acthar, the company’s star drug.
NEW YORK, NY / ACCESSWIRE / May 20, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Teva Pharmaceuticals Industries Limited ("Teva" ...
Roche (RHHBY) gains an FDA nod for the sNDA of its leukemia drug, Venclexta, in combination with Gazyva for the treatment of previously untreated chronic lymphocytic leukemia.
Teva or Endo: Which Is the Better Pick in May?(Continued from Prior Part)Copaxone’s revenue erosionOn its first-quarter earnings conference call, Teva Pharmaceutical (TEVA) reaffirmed its 2019 global sales guidance of $1.30 billion for its
Teva or Endo: Which Is the Better Pick in May?(Continued from Prior Part)Ajovy’s market expansion strategyOn April 2, Teva Pharmaceutical (TEVA) issued a press release announcing the European Union’s approval of its monthly and quarterly dosages
Teva or Endo: Which Is the Better Pick in May?(Continued from Prior Part)Teva’s performanceIn the first quarter, Teva Pharmaceutical (TEVA) reported revenue of $4.29 billion, a YoY (year-over-year) fall of 15.20% and $89.76 million lower than the
Teva or Endo: Which Is the Better Pick in May?(Continued from Prior Part)EPS and EBITDA guidanceIn its first-quarter earnings investor presentation, Teva Pharmaceutical (TEVA) reiterated its non-GAAP (generally accepted accounting principles) EPS
Teva or Endo: Which Is the Better Pick in May?Share price movementsOn May 13, Teva Pharmaceutical (TEVA) closed at $12.23, 14.83% lower than its previous day’s close, 12.89% lower than its 52-week low of $14.04, and 52.89% lower than its 52-week
Stocks took a beating thanks to China trade worries, with Boeing falling on further 737 MAX concerns and Teva Pharmaceutical and other generic-drug makers tumbling after getting sued.
Teva stock, already down 20% year to date, was on pace to set a 52-week low on Monday, a day after 44 states, led by Connecticut, announced an antitrust lawsuit against 20 generic-drug manufacturers
Boeing shares dropped more than 4.5% after the editor of Chinese newspaper Global Times said China could single out the aerospace giant as the U.S.-China trade war continues. Earlier in the day, China decided it would hike tariffs on $60 billion worth of U.S. imports starting June 1. ADT ADT — ADT dropped more than 6% after Morgan Stanley downgraded the stock to equal weight from overweight.
Forty-four states, led Connecticut Attorney General William Tong, claim 20 drug companies, including Teva, "systematically" divided up the market for generic drugs to avoid competing with one another.
Pinterest, Teva Pharmacetucals, Amazon, Disney and Flywheel Sports are the companies to watch.
Check out the companies making headlines before the bell: Qualcomm QCOM — The chip maker awarded its executive team stock bonuses after its multibillion settlement with Apple AAPL over long-standing patent disputes.